Cargando…
Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154710/ https://www.ncbi.nlm.nih.gov/pubmed/31858596 http://dx.doi.org/10.1111/bjh.16345 |